In leukemia, FTO inhibitors block the FTO/m6A/MYC/CEBPA signaling axis, inhibiting the autologous renewal of tumor stem cells and the expression of the immune checkpoint LILRB4 and immune evasion, thereby enhancing the cytotoxicity of T cells [245]. Here, FTO is linked to leukemia.